E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10047263 |
E.1.2 | Term | Ventilation pneumonitis |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Incidence reduction of early VAP with short term amoxicillin-clavulanic acid in patients treated with hypothermia after out-of-hospital cardiac arrest |
|
E.2.2 | Secondary objectives of the trial |
Impact on :
*Early nosocomial infectious complications
*Incidence and epidemiology of late VAP
*Mortality
*Antibiotics consumption
*Intestinal microbiota
*Ventilator free days
*Safety
*Cost of each strategy
*Biomarkers sub-study
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Prevention of early ventilator-associated pneumonia with antibiotic therapy in patients treated with mild therapeutic hypothermia after cardiac arrest : Interest of biomarkers.
In this cohort of 192 out-of-hospital resuscitated cardiac arrest secondary to shockable rhythm patients and treated with therapeutic hypothermia, new inflammation or infection biomarkers could permit: 1/ to discriminate true infection (related to very early VAP occurrence, i.e. within 3 days post cardiac arrest) from isolated post-cardiac arrest inflammation syndrome (related to SIRS); 2/ to assess their prognostic value in terms of survival and favourable neurologic outcome predictions. |
|
E.3 | Principal inclusion criteria |
-Patients older than 18 years-old, mechanically ventilated after an out-of-hospital resuscitated cardiac arrest secondary to shockable rhythm
-Hospitalized in an ICU
-Mild therapeutic hypothermia procedure scheduled (24 to 36 hours) before randomization
-Delay from ROSC to randomisation < 6 hours
-Consent from family members or emergency consent
|
|
E.4 | Principal exclusion criteria |
-Pregnant women
-Out-of-hospital cardiac arrest secondary to non shockable rhythm (mild therapeutic hypothermia not yet “evidence based”)
-In-hospital cardiac arrest
-Need for cardiac support by cardiopulmonary bypass
-Ongoing antibiotic therapy or during the week before
-Ongoing or concomitant pneumonia
-Known chronic colonization with MRB
-Known severe allergy to beta-lactame antibiotics (Quincke edema, shock) and amoxicillin-clavulanic acid use contraindications
-Previous lung disease making radiological interpretation difficult for VAP diagnosis
-Predictable decision of early care limitation or withdrawal (< 7 days)
-Moribund patient
-Participation in any other clinical study that involves the administration of medication at the time of randomization or during the 30 days prior to study start or which can influence primary outcome
- Patient under guardianship or curatorship |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Onset of an early VAP (during 7 first days of hospitalization).
As VAP definition remains controversial and difficult (overlap between colonization, VAT and VAP) with different approaches, some using scoring and others microbiological quantitative thresholds, sites will be asked to document all VAP or suspected VAP episode and use routine site diagnosis tools to treat patients.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
-Nosocomial infectious complications not related to VAP
-Late VAP (analysed by the independent blind adjudication committee)
-Mortality at D28 and cause of death (neurological or extra-neurological)
-Intestinal carriage of MRB at D7 which were not present at D0
-Antibiotics consumption in ICU, expressed as the number of days with antibiotics
-Length of stay in the ICU
-Ventilator-free days at D28. This outcome will be assessed applying the following rules:
oThe period of interest will begin at the randomization date
oPatients who die before day 28 will be affected a 0 value
oDays between two mechanical ventilation episode will be taken into account
oA successful extubation will be defined as a spontaneous breathing 48h after extubation
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 16 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |